Biodesix Announces Third Quarter 2024 Results and Highlights
01. November 2024 06:00 ET
|
Biodesix, Inc.
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and...
Biodesix to Participate in Three Investor Conferences in November
29. Oktober 2024 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive...
Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR
26. März 2019 09:00 ET
|
Biodesix, Inc.
BOULDER, Colo., March 26, 2019 (GLOBE NEWSWIRE) -- Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib,...
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
12. November 2018 09:00 ET
|
Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...
Biodesix Advances ORACLE Registry for Lung Nodule Cancer Test
30. Oktober 2018 08:27 ET
|
Biodesix, Inc.
Noninvasive Test to Rule Out Cancer Expected to Lower Patient Anxiety and Costs BOULDER, Colo., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Biodesix® today provided an update on the Observational Registry...
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
22. Oktober 2018 03:00 ET
|
Biodesix, Inc.
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix®...
Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication
10. September 2018 08:18 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Biodesix today announced newly published data showing the noninvasive BDX-XL2 test, currently in development, could reduce the number of...
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
29. August 2018 08:21 ET
|
Biodesix, Inc.
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...
Society for Advanced Bronchoscopy Commits to Enhance Education and Practice Excellence as U.S. Demand for Bronchoscopy Procedures Increases
29. Mai 2018 12:22 ET
|
Biodesix, Inc.
TAMPA, Fla., May 29, 2018 (GLOBE NEWSWIRE) -- Bronchoscopy professionals in the United States need greater educational and practice-building support to ensure continued delivery of high-quality care...
Society for Advanced Bronchoscopy Meets May 20 to Address “Hot Topics in Advanced Bronchoscopy”
15. Mai 2018 09:21 ET
|
Biodesix, Inc.
TAMPA, Fla., May 15, 2018 (GLOBE NEWSWIRE) -- The Society for Advanced Bronchoscopy (SAB) will hold its second meeting, “Hot Topics in Advanced Bronchoscopy,” on Sunday, May 20th at the Hotel...